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Arjun K Ravi1*, Shruti Khurana1, Jonathan Lemon2, Jonathan Plumb2, George Booth2, Louise Healy3,
Matthew Catley3, Jørgen Vestbo2,4 and Dave Singh1,2Abstract
Background: COPD patients have increased numbers of macrophages and neutrophils in the lungs. Interleukin-6
(IL-6) trans-signaling via its soluble receptor sIL-6R, governs the influx of innate immune cells to inflammatory foci
through regulation of the chemokine CCL3. We hypothesized that there would be enhanced levels of IL-6, sIL-6R
and CCL3 in COPD sputum.
Methods: 59 COPD patients, 15 HNS and 15 S underwent sputum induction and processing with phosphate
buffered saline to obtain supernatants for IL-6, sIL-6R and CCL3 analysis. Cytoslides were produced for differential
cell counting and immunocytochemistry (COPD; n = 3) to determine cell type surface expression of the CCL3
receptors CCR5 and CCR1.
Results: COPD patients expressed higher levels (p < 0.05) of sIL-6R and CCL3 compared to controls (sIL-6R medians
pg/ml: COPD 166.4 vs S 101.1 vs HNS 96.4; CCL3 medians pg/ml: COPD 117.9 vs S 0 vs HNS 2.7). COPD sIL-6R levels
were significantly correlated with sputum neutrophil (r = 0.5, p < 0.0001) and macrophage (r = 0.3, p = 0.01) counts.
Immunocytochemical analysis revealed that CCR5 and CCR1 were exclusively expressed on airway macrophages.
Conclusion: Enhanced airway generation of sIL-6R may promote IL-6 trans-signaling in COPD. Associated
upregulation of CCL3 may facilitate the recruitment of macrophages into the airways by ligation of CCR1 and CCR5.
Keywords: COPD, Sputum, Two-step sputum processing, Interleukin-6, sIL-6R, CCL3Introduction
Chronic Obstructive Pulmonary Disease (COPD) arises
due to an abnormal inflammatory response to inhaled
noxious particles, such as cigarette smoke [1]. There are
increased numbers of neutrophils and macrophages in
the airways of COPD patients [2]. These cells organize
the innate immune response, and contribute to inflam-
mation through the secretion of cytokines, chemokines,
elastolytic enzymes and reactive oxygen species [3,4].
The cytokine interleukin-6 (IL-6) exerts pro-inflammatory
effects through the activation of JAK-STAT (Janus Kinase –
Signal Transducer and Activator of Transcription) sig-
naling [5]. IL-6 initiates the acute phase response, stimu-
lating the secretion of C-reactive protein (CRP) [6]; IL-6
and CRP levels are increased during acute exacerbations* Correspondence: ARavi@meu.org.uk
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reproduction in any medium, provided the orof COPD [7]. There is also evidence that increased serum
and broncho-alveolar lavage (BAL) IL-6 levels are associ-
ated with lower lung function in COPD [8], suggesting a
role for IL-6 in the chronic inflammatory processes that
cause disease progression.
The IL-6 receptor has two components: an IL-6 bind-
ing domain (IL-6R) and a membrane bound signal trans-
ducing element (gp130) [9]. IL-6R can be proteolytically
cleaved from the cell membrane by the metalloprotein-
ase ADAM17 (A Disintegrin and Metalloproteinase-17)
to generate a soluble form (sIL-6R) [10]. IL-6 bound to
sIL-6R forms a complex that binds to cell surface gp130
to initiate signal transduction, a process known as trans-
signaling [11]. The role of IL-6 in inflammation is critic-
ally dependent on sIL-6R levels; IL-6 trans-signaling
controls macrophage recruitment during acute inflam-
mation [12]. Furthermore, IL-6 signaling can be upregu-
lated by increased sIL-6R levels without a change in IL-6
levels [12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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[13], acting through the receptors CCR1 and CCR5.
There is evidence that CCL3 levels are increased in the
lungs of COPD patients; CCL3 gene expression is in-
creased in COPD bronchial epithelial cells compared
with healthy controls [14,15] and a small study recently
showed increased sputum supernatant CCL3 levels in
COPD patients [15]. CCL3 regulates the expression of
IL-6; CCL3 stimulation increases IL-6 expression in peri-
toneal macrophages [16]. Additionally, IL-6 knock-out mice
have significantly reduced CCL3 and macrophage counts in
BAL after the intra-tracheal administration of bleomycin
[17]. The expression and activity of IL-6 and CCL3 appear
to be closely associated, and involved in the regulation of
macrophage numbers during inflammation [17].
We hypothesized that IL-6, sIL-6R and CCL3 levels are
increased in the airways of COPD patients. We therefore
investigated the levels of these proteins in induced sputum
from COPD patients compared to controls. We also stud-
ied the expression of the CCL3 receptors, CCR1 and CCR5,
on airway macrophages and neutrophils to determine
the target immune cell for this chemokine in the lungs
of COPD patients.Methods
Subjects
59 COPD patients, 15 smokers (S) and 15 healthy non-
smokers (HNS) were recruited from primary care between
January and August 2011. COPD patients had been diag-
nosed according to current guidelines [1]. S with >10 pack
year history and HNS had normal lung function. Pa-
tients with a history of asthma, respiratory tract infec-
tion or COPD exacerbation within the preceding six
weeks were excluded. The research was approved by a
local ethics committee (Greater Manchester (East): Ap-
proval number 05/Q140241) and all participants pro-
vided written informed consent.Study design
COPD patients performed the following procedures on a
single study visit: spirometry, body plethysmography,
transfer factor/transfer coefficient, 6 minute walk test
(6MWT), St George’s Respiratory Questionnaire (SGRQ)
[18], modified Medical Research Council dyspnoea scale
(mMRC) [19], COPD Assessment Tool (CAT) [20], Med-
ical Research Council chronic bronchitis questionnaire
[21] and sputum induction. S and HNS underwent spir-
ometry and sputum induction only. 6 HNS underwent
venesection to provide blood for monocyte isolation
(demographic data presented in Additional file 1: Table
S1). Permission was obtained for the utilization of SGRQ
and CAT (Additional file 2: Terms of use).Pulmonary function
Maximum expiratory flow volume measurements were
performed in triplicate on a Vitalograph gold standard
wedge bellows spirometer; we recorded the highest FEV1
(forced expiratory volume in 1 second) and FVC (forced
vital capacity). Readings were repeated after 20 minutes
following the inhalation of 200 μg salbutamol via spacer.
FRC (functional residual capacity), TLC (total lung cap-
acity) and IC (inspiratory capacity) were measured pre-
bronchodilator using a constant volume plethysmograph
(Sensormedics Vmax Encore V62J body plethysmograph)
according to ERS standards [22]. Carbon Monoxide Diffu-
sion Capacity (DLCO) and Transfer coefficient (KCO)
were determined using the Sensormedics Vmax Encore
V62J body plethysmograph) according to ERS standards
[23]. The 6MWT was performed according to ATS stan-
dards [24].
Sputum induction and processing
Sputum was induced and processed by the two-step
method (initial phosphate buffered saline (PBS) wash
followed by the addition of Dithiothreitol (DTT)) as pre-
viously described [25]; this method avoids the unwanted
effects of DTT on immunoassays applied to the superna-
tants. Cytoslides were produced to determine differential
cell count and for immunocytochemistry.
For differential cell counts, cytoslides were air dried,
fixed with methanol and stained with Rapi-diff (Triangle,
Skelmersdale, UK). Four hundred non-squamous cells
were counted and the results expressed as a percentage
of the total cell count (TCC), and a total cell count per
gram of sputum (TCC/g). Unfixed cytoslides were stored
frozen at −80°C prior to immunocytochemistry (ICC).
Cytokine measurements
Levels of IL-6, sIL-6R and CCL3 in PBS processed spu-
tum supernatant were measured using Meso Scale Dis-
covery® (MSD) immunoassay (Gaithersburg (MD)-USA).
Analysis was performed at UCB (Slough, UK). The lower
limits of quantification (LLOQ) were: IL-6 (1.6 pg/ml),
sIL-6R (0.1 pg/ml) and CCL3 (15.0 pg/ml). Levels below
the LLOQ were assigned values of 0 pg/ml. It has previ-
ously been shown that the measurement of IL-6, sIL-6R
and CCL3 in PBS processed sputum using MSD pro-
vides satisfactory recovery of spiked analyte [25].
Immunocytochemistry
ICC was performed on sputum cytoslides from 3 COPD
patients to identify cell-type specific expression of the
binding receptors for CCL3 (CCR1 and CCR5). Cells
were fixed in 4% paraformaldehyde (Sigma, Poole, UK).
Rabbit anti-human CCR1 and CCR5 (AbCam, Cambridge,
UK) primary antibodies diluted in 1.5% normal serum
(Vector Labs, Peterborough, UK) were applied overnight
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bating sections in 3% H2O2 (hydrogen peroxide, Sigma)
for 30 minutes at room temperature. CCR1 and CCR5
were detected using biotinylated goat anti-rabbit im-
munoglobulin (IgG) secondary antibody (Vector Labs)
in conjunction with an avidin-biotin peroxidase com-
plex (Vector Labs). CCR1 and CCR5 were visualised
using 3,3′-diaminobenzidine (DAB) substrate and coun-
terstained with modified Gill’s haematoxylin. Omission
of primary antibody from staining protocol and substitu-
tion of primary antibody with an isotype control antibody
(Vector Labs) were used as negative controls. Digital
micrographs were obtained using a Nikon Eclipse 80i
microscope (Nikon UK Ltd, Surrey UK) equipped with a
QImaging digital camera (Media Cybernetics, Marlow,
UK) and ImagePro Plus 6.0 software (Media Cybernet-
ics). The number of cells that stained positively for
CCR1 and CCR5 were determined using the manual-tag
function in ImagePro Plus. 100 cells were counted per
slide.
CD14+ monocyte isolation
50 mls of blood was obtained by venipuncture and col-
lected in a heparinized tube. Peripheral blood mono-
nuclear cells (PBMC) were isolated by Ficoll differential
centrifugation [26]. CD14+ monocytes were positively
selected from the PBMCs by magnetic bead isolation as
previously described [26], and then suspended in either
RPMI (Sigma) or PBS (for ICC and chemotaxis experi-
ments respectively).
CD14+ monocyte CCR1 and CCR5 surface expression
In order to establish whether CCL3 interferes with the
ICC detection of CCR1 and CCR5, we performed an ex-
periment assessing the CCR1 and CCR5 expression on
CD14+ monocytes cultured in the presence of CCL3. 3
HNS donated blood for monocyte isolation.
CD14+ cells were seeded (1×105 cells/well) in a 96-well
plate (Greiner Bio-One, Stonehouse , UK) and incubated
in the presence or absence of rh-CCL3 (recombinant
human CCL3; 1 ng/ml: R&D systems, Abingdon, UK)
for 45 minutes at 37°C and 5% CO2. Cytoslides were
prepared from the cell suspensions and analysed for
CCR1 and CCR5 expression by ICC as described
above. Morphological analysis confirmed CD14+ cells
as monocytes.
Sputum supernatant induced monocyte chemotaxis
An experiment was performed to assess whether an-
tagonism of CCL3 resulted in reduced migration of
CD14+ monocytes towards PBS processed COPD spu-
tum supernatant.
3 HNS donated blood for monocyte isolation. The
chemotaxis assay was performed using 96-well Multiscreen™MIC plates incorporating 5 μm pore diameter polycar-
bonate filter membranes (Merck-Millipore, Watford-
UK) based on the method of transwell diffusion [27,28].
CD14+ monocytes (1 × 105 cells/well) were applied to
the upper plate and incubated with either anti-human
CCR5 monoclonal antibody (mAb) (20 μg/ml, R&D Sys-
tems) or PBS alone. PBS sputum supernatant obtained
from 3 individuals with COPD was pooled and diluted
in a 1:10 ratio with PBS. Diluted sputum supernatant
was applied to the wells of the lower plate in the pres-
ence/absence of anti-human CCL3 mAb (0.5 μg/ml,
R&D Systems). The two plates were incubated separ-
ately for 60 minutes at 37°C then sandwiched together
and incubated for a further 18 hours. Migrated cells in
the lower plate were collected, incubated with lysis buf-
fer containing Quant-IT PicoGreen fluorescent dsDNA
binding probe (Life Technologies, Paisley-UK) and ana-
lysed using a BMG LabTech FluoStar Optima optical
density plate reader. CD14+ monocyte chemotaxis was
expressed as a proportion (%) of maximum CD14+
monocyte migration (CD14+ cells added directly to the
wells of the lower plate) [28]. All conditions were
assayed in triplicate. Concentrations of the neutralizing
monoclonal antibodies used were determined based on
data obtained from neutralization experiments (ND50)
conducted by the manufacturer.Statistical analysis
Sputum supernatant protein data were non-parametric,
while sputum cell count data was parametric with the
exception of eosinophil counts. When 3 groups were
compared, one-way analysis of variance (ANOVA) or
Kruskal-Wallis tests were performed followed by the re-
spective application of Tukey’s or Dunn’s post-tests.
Mann–Whitney U tests were applied where appropriate.
The effects of CCL3 and CCR5 inhibition on % CD14+
monocyte chemotaxis were analysed using paired para-
metric t-tests. Each individual value from triplicate re-
cordings using monocytes from 3 blood samples was
included in the analysis. Univariate correlations of the
data were performed using the Spearman rank test. P
values <0.05 were considered to be significant. Analysis
was performed using Prism version 5.0 (GraphPad
software, San-Diego, USA) and SPSS version 19.0 (SPSS
Inc., Chicago, USA).Results
Subject demographics
The clinical characteristics of the study subjects are
summarized in Table 1. The COPD patients were signifi-
cantly older than the control groups, although the smok-
ing pack year history was similar in COPD patients and
S. There were 12 patients with GOLD stage I disease
Table 1 Demographic details of study participants
COPD (n = 59) S (n = 15) HNS (n = 15) p-value
Sex (F:M) 23:36 8:7 4:11 -
Age* 67 (45–75) 52 (38–62) 32 (19–75) p < 0.0001
Pack years smoked*§ 34.9 (12.5-122.2) 29 (15–67) 0 ns
Current smokers (%) 41 100 0 -
ICS users (%) 67.8 - - -
Chronic Bronchitis (n) (%) 35 (59%) - - -
FEV1% predicted1a 61.6 (18.1) 95.7 (13.0) 116.7 (13.8) p < 0.0001
FEV1/FVC %1* 51.0 (28.9-67.0) 74.8 (70.5-80.8) 85.7 (72.6-101.6) p < 0.0001
FEV1 % predicted2a 64.5 (17.2) 98.64 (12.1) 117.9 (14.3) p < 0.0001
FEV1/FVC %2* 57.1 (25.8-69.6) 73.0 (70.2-82.5) 86.1 (80.7-93.7) p < 0.0001
IC (L)1a 2.2 (0.7) - - -
TLC% predicted1* 102.3 (8.4-164.7) - - -
KCO% predicted1a 88.1 (25) - - -
6MWT distance (m)* 387 (28–540) - - -
SGRQ (total)a 37 (19.8) - - -
mMRCa 1.2 (1) - - -
CATa 17.5 (7.9) - - -
*Data presented as median (range). aData presented as mean (SD). 1Pre-bronchodilator. 2Post-bronchodilator. Explanation of abbreviations: IC = Inspiratory
capacity, TLC = total lung capacity, KCO = transfer coefficient, 6MWT = 6 minute walk test, SGRQ = St George’s respiratory questionnaire, mMRC =modified Medical
Research Council Dyspnoea score, CAT = COPD assessment tool, ns = not significant. The statistical significance of differences between groups was determined
using either ANOVA + Tukey’s multiple comparison test or Kruskal-Wallis + Dunn’s post-test (for analysis of parametric and non-parametric data respectively).
§Mann–Whitney U test was performed to assess the statistical significance of differences in pack-year smoking history between COPD & S.
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GOLD stage IV.Sputum counts
COPD sputum samples had increased neutrophil percent-
age and cell count/g compared to S (p < 0.001) and HNS
(p < 0.001) – see Table 2. COPD sputum samples also had
increased eosinophil percentage and cell count/g com-
pared to S (p < 0.0001) and HNS (p < 0.0001), and aTable 2 Sputum cell counts
COPD S
Neutrophil% 69.5 (23.8)* 54 (2
Macrophage% 26.6 (23.7)**§ 48.7
Eosinophil %^ 1.3 (0–23.3)*† 0 (0–
Lymphocyte % 0.1 (0.4) 0.1 (0
TCC*106 3.3 (3.6)** 2.9 (4
TCC/g*106 3.5 (3) 2.9 (3
Neutrophil TCC/g*106 2.6 (2.8)*† 0.3 (0
Macrophage TCC/g*106 0.7 (0.7) 0.5 (0
Eosinophil TCC/g*106^ 0.03 (0–1.5) ‡¶ 0 (0–
Lymphocyte TCC/g*106 0.003 (0.007) 0.001
Data is presented as mean (SD) with the exception of ^eosinophil % and eosinophi
TCC Total cell count, TCC/g Total cell count/gram *p < 0.001 COPD vs HNS, **p < 0.0
vs HNS, ¶ p < 0.0001 COPD vs S.reduced macrophage percentage compared to S (p < 0.05)
and HNS (p < 0.05).
Sputum supernatant measurements
Sputum supernatant levels of IL-6 were increased in S
(median 217.8 pg/ml) compared to COPD patients (me-
dian 87.3 pg/ml, p < 0.05) and HNS (median 50.9 pg/ml,
p < 0.01) (see Figure 1). COPD patients had numerically
higher levels of IL-6 compared to HNS, but this differ-
ence did not reach statistical significance (p = 0.068).HNS p-value (ANOVA)
5.1) 38.7 (27.2) 0.0003
(28.4) 46.3 (33.1) 0.0033
1.5) 0 (0–2.5) <0.0001
.5) 0.02 (0.06) ns
.4) 0.7 (0.7) ns
.2) 2.4 (2.2) ns
.2) 0.3 (0.2) 0.0004
.8) 0.4 (0.5) ns
0.02) 0 (0–0.01) <0.0001
(0.002) 0.0001 (0.001) ns
l TCC/g which are presented as median (range). Explanation of abbreviations:
5 COPD vs HNS, §p < 0.05 COPD vs S, †p < 0.001 COPD vs S, ‡p < 0.0001 COPD
Figure 1 Sputum Cytokine Concentrations. Concentrations of (A)
IL-6, (B) sIL-6R and (C) CCL3 in induced sputum from HNS, S and
COPD patients. Each dot represents the data from an individual
patient. The horizontal bar represents the median value. The dotted
line represents the lower limit of quantification (LLOQ) for the
respective analytes. (B) 1 COPD subject had sIL-6R levels registering
below the LLOQ. (C) 6 HNS and 12 S had CCL3 levels registering
below the lower limit of quantification.
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patients (median 166.4 pg/ml) compared to than S (me-
dian 101.1 pg/ml, p < 0.05), although the difference com-
pared to HNS did not reach statistical significance
(median 96.4 pg/ml, p = 0.10). COPD patients had signifi-
cantly higher levels of CCL3 (median 117.9 pg/ml) com-
pared to S (median 0 pg/ml, p < 0.0001) and HNS (median
19.9 pg/ml, p < 0.001).
In COPD sputum, the association between IL-6 and
IL-6R levels did not reach statistical significance (r = 0.2,
p = 0.06). Both IL-6 and sIL-6R had statistically signifi-
cant but weak (r = 0.4), positive correlations with CCL3
levels in COPD (see Figure 2). The relationships between
these supernatant proteins and sputum cells in COPD
patients was also analysed; the strongest associations
were observed between sputum sIL-6R levels and total
cell count, and the total number of neutrophils (see
Figure 3), macrophages and eosinophils (see Additional
file 3: Table S2).
35 (59%) of the COPD patients in this study had
chronic bronchitis. We observed that subjects withFigure 2 Univariate Correlations of COPD sputum CCL3 with
IL-6 and sIL-6R. Univariate correlation between sputum (A) IL-6 and
(B) sIL-6R with CCL3 in COPD patients. r represents the Spearman
Rank correlation coefficient. Each dot represents the data for an
individual patient.
Figure 3 Univariate Correlation of COPD sputum sIL-6R with
sputum neutrophil TCC/g. Univariate correlation between COPD
sputum sIL-6R and neutrophil TCC/g. r represents the Spearman
Rank correlation coefficient. Each dot represents the data for an
individual patient.
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of all measured sputum cytokines compared to patients
without chronic bronchitis; these differences were not
statistically significant (see Additional file 4: Table S3).
There were no significant associations between sputum
IL-6, sIL-6R and CCL3 levels with FEV1% predicted, ex-
acerbation rate, 6MWT distance, SGRQ, mMRC and
CAT in COPD patients (p > 0.05 for all analysis, data not
shown). The levels of these supernatant proteins also did
not differ in COPD patients who were ICS (inhaled cor-
ticosteroid) users compared to those not using ICS, or in
current smokers compared to ex-smokers (p > 0.05 for
all comparisons, data not shown).Expression of CCR1 and CCR5 on sputum leucocytes
As COPD patients had increased sputum CCL3 levels, we
were interested to investigate the expression of the CCL3
receptors. ICC using COPD sputum (n = 3) showed that
CCR1 and CCR5 were expressed in sputum macrophages;
Figure 4 shows a representative sample with positive stain-
ing for macrophages but no staining on neutrophils. All
sputum macrophages expressed CCR1 and CCR5.A B
Figure 4 CCR1 and CCR5 expression of sputum inflammatory cells. Re
inflammatory cells. Immunocytochemical labeling on sputum inflammatory
3,3′-diaminobenzidine (DAB) substrate (brown). Arrows indicate CCR1 (A) aTo confirm that the CCR1 and CCR5 antibodies bind to
their respective chemokine receptors irrespective of recep-
tor occupancy status, we used CD14+ peripheral blood
monocytes isolated from HNS (n = 3); these cells expressed
CCR1 and CCR5 (see Additional file 5: Figure S1). CCR1
and CCR5 expression did not change after culture with
CCL3 or media alone.CD14+ monocyte chemotaxis
The mean level of CD14+ monocyte migration towards
COPD PBS sputum supernatant was 13.5% (see Figure 5).
Levels of CD14+ monocyte migration were significantly
reduced by anti-human CCL3 mAb (9.0%, p = 0.01) and
anti-human CCR5 mAb (4.7%, p < 0.0001).Discussion
The levels of CCL3 in sputum supernatants were signifi-
cantly increased in COPD patients compared to both S
and HNS. Soluble IL-6R levels were significantly in-
creased in COPD patients compared to S. These results
indicate a potential role for IL-6 trans-signaling and
CCL3 in COPD pulmonary inflammation. The CCL3
receptors CCR1 and CCR5 were expressed on airway
macrophages but not neutrophils. Antagonism of CCL3
resulted in a significant reduction in CD14+ monocyte
migration towards COPD sputum supernatant implicat-
ing this chemokine in the processes that control mono-
cyte/macrophage trafficking and positioning within the
lungs of COPD patients.
Previous studies of IL-6 levels within the lungs of
COPD patients have omitted to study the levels of sIL-
6R [7,25]. This soluble receptor is an important compo-
nent of the IL-6 signaling pathway; increased sIL-6R
levels alone, without a change in IL-6 levels, can upregu-
late IL-6 signaling [12]. We found increased sIL-6R
levels in COPD patients compared to S, with the differ-
ence between COPD patients and HNS failing to reach
statistical significance (p = 0.1). Nevertheless, our results
suggest that IL-6 trans-signaling may be increased in the
airways of COPD patients, facilitating the actions of IL-6
through JAK-STAT activation [5].C
presentative images of (A) CCR1 and (B) CCR5 expression on sputum
cells from COPD patients (n = 3). CCR1 and CCR5 were detected using
nd CCR5 (B) immunoreactive cells. (C) Negative control slide.
Figure 5 Effect of CCL3 antagonism on migration of CD14+
monocytes towards COPD sputum supernatant. Assessment of
CD14+ monocyte migration towards COPD PBS sputum supernatant
in the presence of anti-human CCL3 mAb and anti-human CCR5
mAb. Peripheral blood CD14+ monocytes were isolated from three
HNS. Chemotaxis is presented as the percentage of maximum
chemotaxis (CD14+ monocytes added directly to wells of the lower
insert of the chemotaxis plate) and is described as mean (SD). Data
represents the results from three independently conducted experiments.
Statistical significance of differences in %CD14+ monocyte chemotaxis
observed between control (PBS sputum supernatant alone) and
experimental conditions (+CCL3 mAb or + CCR5 mAb) was
determined by application of paired parametric t-tests.
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brane following proteolytic cleavage by ADAM17 [10]. It
has been demonstrated previously [29], and confirmed
here, that the sputum neutrophil total cell counts are
raised in COPD patients compared to controls; increased
neutrophil numbers may contribute to the greater sIL-
6R levels observed in COPD patients. This possibility is
supported by the significant associations between sIL-6R
levels and neutrophil total cell count (Figure 3).
COPD patients had significantly increased sputum abso-
lute neutrophil counts compared to healthy controls.
There was a numerical increase in the absolute sputum
macrophage count in COPD patients, but this was not sta-
tistically significant. It is well known that macrophage
numbers are elevated in the lungs of COPD patients com-
pared with healthy controls [2,30]. However, in sputum
samples there is a greater relative increase in neutrophil
compared to macrophage absolute counts, leading to an
increased percentage of neutrophils.IL-6 levels were significantly increased in S compared to
HNS, indicating that IL-6 is part of the innate immune re-
sponse activation that occurs in smokers with normal lung
function. Similarly, mice exposed to cigarette smoke have
increased pulmonary IL-6 levels compared to air-exposed
control mice [31]. IL-6 levels were lower in COPD pa-
tients compared to S. Blunting of the innate immune re-
sponse in COPD patients has been demonstrated in
alveolar macrophages [32,33] suggesting that persistent
and long term airway inflammation leads to down-
regulation of certain components of the innate immune
response. There was a great spread of results for IL-6 in
COPD; it is possible that IL-6 plays an important role in
airway inflammation in a subgroup of COPD patients
only. It is increasingly recognized that COPD comprises
different phenotypes of disease [34], and IL-6 may play
an important role in specific phenotypes [7,35]. It has
been shown that the levels of IL-6 in BAL are highest in
patients with severe COPD [8]. The majority of our pa-
tients had moderate COPD, and it is possible that in-
creased IL-6 levels would be more apparent in patients
with more severe disease. Furthermore, IL-6 in conjunc-
tion with IL-17 upregulates expression of the mucins
MUC5AC and MUC5B by epithelial cells, and so IL-6
may be more important in COPD patients with mucus
hypersecretion [36].
Chronic bronchitis is associated with increased airway
inflammation and poorer clinical outcomes in COPD
[37,38]. We observed no significant difference between
COPD patients with chronic bronchitis compared to
those without for IL-6, sIL-6R and CCL3 levels. Monsό
[39] observed that 22% of clinically stable COPD pa-
tients with chronic bronchitis were found to have bacter-
ial colonization of the lower airways. Increases in the
airway bacterial load in COPD patients are associated
with elevation in the concentrations of certain inflam-
matory cytokines in the sputum [40], including IL-6. We
did not assess sputum microbiology, and so were unable
to study the relationships between bacterial load and the
levels of IL-6, sIL-6R and CCL3.
CCL3 levels were significantly elevated in sputum super-
natants of COPD patients compared with healthy controls.
It has previously been reported in a small study (with 29
COPD patients, 12 S and 6 HNS) which used DTT proc-
essed sputum [15] that COPD patients had higher levels of
sputum CCL3 than HNS. We definitively show increased
CCL3 levels in COPD sputum using a larger sample size
and PBS processed sputum in order to avoid any effect of
DTT on immunoassays. Increased CCL3 in COPD sputum
may derive from the bronchial epithelium, as it has been re-
ported that COPD bronchial epithelial cells express in-
creased CCL3 mRNA levels compared with controls [14].
CCL3 is a known chemoattractant for monocytes and
macrophages. Wang et al. [15] reported overall increased
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density analysis of immunohistochemistry performed on
sputum cells from COPD patients and controls, but did
not report the cell type expressing CCR5. We found that
the CCL3 receptors CCR1 and CCR5 were exclusively
expressed on sputum macrophages and not neutrophils,
further implicating CCL3 in controlling macrophage
chemotaxis in the airways of COPD patients. Furthermore,
we demonstrated that blockade of CCL3 and its receptor
CCR5 attenuated the migration of CD14+ monocytes to-
wards COPD sputum supernatant. This confirms the role
of the CCL3 present in COPD supernatant as a monocyte
chemoattractant.
It has previously been reported that approximately 45%
of COPD bronchoalveolar lavage neutrophils express
CCR5 [41]. Pre-apoptotic neutrophils have been demon-
strated to upregulate expression of CCR5 with a view to
‘soaking-up’ CCL3 as part of the resolution phase of an
acute inflammatory response [41]. Therefore, even if
CCR5 were expressed on the surface of neutrophils, CCL3
may not be functioning as a chemoattractant for these
cells. Our finding that CCL3 levels did not correlate with
sputum neutrophil counts further substantiates the notion
that it is not acting as a chemoattractant for sputum
neutrophils.
Conclusion
We report increased CCL3 levels in COPD patients, and
demonstrate that CCR1 and CCR5, the receptors for this
chemokine, are expressed on lung macrophages. Block-
ade of CCL3 resulted in reduced chemotaxis of CD14+
cells towards COPD sputum supernatant. These findings
suggest a prominent role for CCL3 in the upregulation
of macrophage numbers seen in the lungs of COPD pa-
tients. Furthermore, sIL-6R levels were increased in
COPD patients, suggesting an increase in IL-6 trans-
signaling. IL-6 promotes chronic inflammation through
a variety of mechanisms [42–44], and it appears that in-
creased sIL-6R plays a role in mediating these effects in
the lungs of COPD patients.Additional files
Additional file 1: Table S1. Depicts the demographic details of the
6HNS who donated blood for CD14+ monocyte isolation.
Additional file 2: Terms of use.
Additional file 3: Table S2. Depicts univariate correlatons between
sputum inflammatory cells and sputum cytokines measured in COPD
sputum supernatant.
Additional file 4: Table S3. Depicts comparisons of sputum cytokine
levels in COPD patients with chronic bronchitis compared to those
without chronic bronchitis.
Additional file 5: Figure S1. Depicts immunocytochemistry for CCR1
and CCR5 expression on isolated CD14+ peripheral blood monocytes in
the presence/absence of CCL3.Abbreviations
ADAM17: A disintegrin and metalloproteinase 17; BAL: Broncho-alveolar
lavage; CAT: COPD assessment tool; COPD: Chronic obstructive pulmonary
disease; DAB: 3,3′-diaminobenzidine; DLCO: Carbon monoxide diffusion
capacity; DTT: Dithiothreitol; FEV1: Forced expiratory volume in 1 second;
FVC: Forced vital capacity; GSK: GlaxoSmithKline; H2O2: Hydrogen peroxide;
HNS: Healthy non-smoker; IC: Inspiratory capacity; ICC: Immunocytochemistry;
ICS: Inhaled corticosteroid; IL-: Interleukin-; JAK: Janus kinase; KCO: Transfer
coefficient; LABC: Lower airway bacterial colonization; LLOQ: Lower limit of
quantification; mAb: Monoclonal antibody; mMRC: Modified Medical
Research Council dyspnoea scale; MSD®: MesoScale Discovery®; ns: Not
significant; PBS: Phosphate buffered saline; PBMC: Peripheral blood
mononuclear cell; rh: Recombinant human; RPMI: Roswell park memorial
institute; S: Smoker; sIL-6R: Soluble interleukin-6 receptor; SGRQ: St George’s
respiratory questionnaire; STAT: Signal transducer and activator of
transcription; TCC: Total cell count; TCC/g: Total cell count/gram; TLC: Total
lung capacity; 6MWT: 6 minute walk test.
Competing interests
Dr Arjun Ravi, Dr Shruti Khurana, Mr Jonathan Lemon, Dr Jonathan Plumb
and Mr George Booth have no conflicts of interest to declare. Dr Louise
Healy and Dr Matthew Catley both work for UCB, Slough (UK). Professor
Dave Singh has received lecture fees, research grants, consultancy fees and
support for conference attendance from various pharmaceutical companies
including AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Roche,
Novartis, Cipla, Almirall and Merck.
Professor Jørgen Vestbo has received lecture fees and consultancy fees from
various pharmaceutical companies including GSK, Nycomed, Chiesi, Novartis,
AstraZeneca and Boehringer Ingelheim.
Authors’ contributions
Conception and Design: AR, DS. Acquisition analysis and Interpretation of
Data: AR, SK, JL, JP, GB, LH, MC, JV, DS. Drafting the manuscript and revising
it critically for important intellectual content: AR, JP, DS. Final approval of the
version to be published: DS, AR, JP, LH. All authors read and approved the
final manuscript.
Acknowledgements
This study was supported by an unrestricted grant from UCB, Slough (UK).
The COPD Assessment Test was reproduced with the permission of
GlaxoSmithKline (GSK, Brentford -UK). GSK owns the Intellectual Property
in the COPD Assessment Test (CAT) (for terms of use of CAT please see
Additional file 2). The SGRQ was reproduced with the permission of St
George’s University (London-UK).
Author details
1Medicines Evaluation Unit, University Hospital of South Manchester NHS
Foundation Trust, University of Manchester, Manchester, UK. 2Manchester
Academic Health Science Centre; University Hospital South Manchester NHS
Foundation Trust; NIHR Respiratory and Allergy Clinical Research Facility,
University of Manchester, Manchester, UK. 3UCB, Slough, Berkshire, UK.
4Department of Cardiology and Respiratory Medicine, Hvidovre Hospital and
University of Copenhagen, Copenhagen, Denmark.
Received: 17 May 2013 Accepted: 19 August 2014
Published: 4 September 2014
References
1. GOLD: Global Strategy for the Diagnosis, Management and Prevention of
Chronic Obstructive Pulmonary Disease; 2011. [cited 2013 05/04]; Available
from: www.goldcopd.org.
2. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniak RM,
Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small airway
obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004,
350(26):2645–2653.
3. Noguera A, Batl S, Iglesias J, Busquets X, Macnee W, Agusti AGN: Enhanced
neutrophil response in chronic obstructive pulmonary disease. Thorax
2001, 56(6):432–437.
4. Atkinson JJ, Lutey BA, Suzuki Y, Toennies HM, Kelley DG, Kobayashi DK, Ljem
WG, Deslee G, Moore CH, Jacobs ME, Conradi SH, Gierada DS, Pierce RA,
Betsujaku T, Senior RM: The role of matrix metalloproteinase-9 in cigarette
Ravi et al. Respiratory Research 2014, 15:103 Page 9 of 10
http://respiratory-research.com/content/15/1/103smoke-induced emphysema. Am J Respir Crit Care Med 2011,
183(7):876–884.
5. Stahl N, Boulton TG, Farrugella T, Ip NY, Davis S, Witthuhn BA, Quelle FW,
Silvennoinen O, Barbieri G, Pellegrini S, Ihle JN, Yancopoulos GD:
Association and activation of Jak-Tyk Kinases by CNTF-LIF-OSM -IL-6 beta
receptor components. Science 1994, 262(5143):92–95.
6. Heinrich P, Castell JV, Andus T: Interleukin-6 and the acute phase
response. Biochem J 1990, 265(3):621–636.
7. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA: Relation of sputum
inflammatory markers to symptoms and lung function changes in COPD
exacerbations. Thorax 2000, 55(2):114–120.
8. Soler N, Ewig S, Torres A, Filela X, Gonzalez J, Zaubet A: Airway
inflammation and bronchial microbial patterns in patients with stable
chronic obstructive pulmonary disease. Eur Respir J 1999, 14(5):1015–1022.
9. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T: Molecular
cloning and expression of an IL-6 signal transducer gp130. Cell 1990,
63(6):1149–1157.
10. Gómez MI, Sokol SH, Muir AB, Bastein J, Prince AS: Bacterial induction of
TNF-α converting enzyme expression and IL-6 receptor α shedding
regulates airway inflammatory signaling. J Immunol 2005,
175(3):1930–1936.
11. Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S: Complex of soluble
human IL-6 receptor/IL-6 upregulates expression of acute phase pro-
teins. J Immunol 1992, 149(6):2021–2027.
12. Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N,
Fuller GM, Topley N, Jones SA: IL-6 and its soluble receptor orchestrate a
temporal switch in the pattern of leucocyte recruitment seen during
acute inflammation. Immunity 2001, 14(6):705–714.
13. Salentin R, Gemsa D, Sprenger H, Kaufmann A: Chemokine receptor
expression and chemotactic responsiveness of human monocytes after
influenza A virus infection. J Leuk Biol 2003, 74(2):252–259.
14. Fuke S, Betsuyaku T, Nasuhara Y, Morikawa T, Katoh H, Nishimura M:
Chemokines in bronchiolar epithelium in the development of chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol 2004,
31(4):405–412.
15. Wang F, He B: CCR1 and CCR5 expression on inflammatory cells is
related to cigarette smoking and chronic obstructive pulmonary disease.
Chin Med J 2012, 125(23):4277–4282.
16. Fahey TJ III, Tracey KJ, Tekamp-Olson P, Cousens LS, Jones WG, Shires GT,
Sherry B: Macrophage inflammatory protein 1 modulates macrophage
function. J Immunol 1992, 148(9):2764–2769.
17. Saito F, Tasaka S, Inoue KI, Miyamoto K, Nakano Y, Ogawa Y, Yamada W,
Ishizaka A: Role of interleukin-6 in bleomycin-induced lung inflammatory
changes in mice. Am J Respir Cell Mol Biol 2007, 38(5):566–571.
18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-completed
measure of health status for chronic airflow limitation: the St
George’s respiratory questionnaire. Am J Respir Crit Care Med 1992,
145(6):1321–1327.
19. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH: The significance of
respiratory symptoms aid the diagnosis of chronic bronchitis in a
working population. BMJ 1959, 2(5147):257–266.
20. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N:
Development and first validation of the COPD Assessment Test.
Eur Respir J 2009, 34:648–654.
21. Medical Research Council: Definition and Classification of chronic
bronchitis for clinical and epidemiological purposes. Lancet 1965,
285(7389):775–779.
22. Wanger J, Clausen JL, Coates A, Pedersen O, Brusasco V, Burgos F, Casaburi
R, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Hankinson J,
Jensen R, Johnson D, MacIntyre N, McKay R, Miller MR, Navjas D, Pellegrino
R, Viegi G: Standardization of the measurement of lung volumes. Eur
Respir J 2005, 26(3):511–522.
23. Macintyre N, Crapo R, Viegi G, Johnson D, van der Grinten C, Brusasco V,
Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J,
Jensen R, McKay R, Miller M, Navajas D, Pederson O, Pellegrino R, Wanger J:
Standardization of the single breath determination of carbon monoxide
uptake in the lung. Eur Respir J 2005, 26(3):720–735.
24. ATS: ATS statement: guidelines for the six-minute walk test. Am J Respir
Crit Care Med 2002, 166(1):111–117.
25. Badafahel M, McCormick M, Saha S, McKenna S, Shelley M, Hargadon B,
Mistry V, Reid C, Brightling CE: Profiling of sputum inflammatorymediators in asthma and chronic obstructive pulmonary disease.
Respiration 2012, 83(1):36–44.
26. Vitale S, Schmid-Alliana A, Breuil V, Pomeranz M, Millet M-A, Rossi B, Scmid-
Antomarchi H: Soluble Fractalkine prevents monocyte chemoattractant
protein-1-induced monocyte migration via inhibition of stress-activated
protein Kinase 2/p38 and matrix metalloproteinase activities. J Immunol
2004, 172(1):585–592.
27. Boyden S: The chemotactic effect of mixtures antibody and antigen on
polymorphonuclear leucocytes. J Exp Med 1962, 115(3):453–466.
28. Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D: LPS challenge
in healthy subjects: an investigation of neutrophil chemotaxis
mechanisms involving CXCR1 and CXCR2. Int Immunopharmacol 2012,
13(3):225–231.
29. Singh D, Edwards L, Tal-Singer R, Rennard S: Sputum neutrophils as a
biomarker in COPD: findings from the ECLIPSE study. Resp Res 2010,
11:77.
30. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE: Increased levels of
the chemokines GROalpha and MCP-1 in sputum samples from patients
with COPD. Thorax 2002, 57(7):590–595.
31. Pauwels NS, Bracke KR, Maes T, Pilette C, Joos GF, Bruselle GG: The role of
interleukin 6 in pulmonary and systemic manifestations in a murine
model of chronic obstructive pulmonary disease. Exp Lung Res 2010,
36(8):469–483.
32. Shaykhiev R, Krause A, Salit J, Strulovici-Barel Y, Harvey B-G, O’Connor TP,
Crystal RG: Smoking dependent reprogramming of alveolar macrophage
polarization: implication for pathogenesis of COPD. J Immunol 2009,
183(4):2867–2883.
33. Armstrong J, Sargent C, Singh D: Glucocorticoid sensitivity of
lipopolysaccharide-stimulated chronic obstructive pulmonary disease
alveolar macrophages. Clin Exp Immunol 2009, 158(1):74–83.
34. Han MK, Agusti A, Calvery P, Celli B, Criner G, Curtis JL, Fabbri LM, Goldin JG,
Jones PW, Macnee W, Make BJ, Rabe KF, Rennard S, Sciurba FC, Silverman
EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ: Chronic obstructive
pulmonary disease phenotypes - the future of COPD. Am J Respir Crit
Care Med 2010, 182(5):598–604.
35. Donaldson GC, Seemungal TAR, Patel IS, Bhowmick A, Wilkinson TMA,
Hurst JR, MacCallum PK, Wedzicha JA: Airway and systemic inflammation
and decline in lung function in patients with COPD. Chest 2005,
128(4):1995–2004.
36. Chen Y, Thai P, Zhao Y-H, Ho Y-S, de Souza MM, Wu R: Stimulation of
airway mucin gene expression by IL-17 through IL-6 Paracrine/Autocrine
loop. J Biol Chem 2003, 278(19):17036–17043.
37. Snoeck-Stroband JB, Lapperre TS, Gosman MME, Boezen HM, Times W, ten
Hacken NHT, Sont JK, Sterk PJ, Hiemstra PS and the Groningen Leiden
Universities Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study
Group: Chronic bronchitis sub-phenotype within COPD: inflammation in
sputum and biopsies. Eur Respir J 2008, 31(1):70–77.
38. de Oca MM, Halbert RJ, Lopez MV, Perez-Padilla R, Tálamo C, Muiño A,
Jardim JRB, Valdivia G, Pertuzé J, Menezes AMB: The chronic bronchitis
phenotype in subjects with and without COPD: the PLATINO study.
Eur Respir J 2012, 40(1):28–36.
39. Monsό E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, Morera J:
Risk factors for lower airway bacterial colonization in chronic bronchitis.
Eur Respir J 1999, 13(2):338–342.
40. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha
JA: Relationship between bacterial colonisation and the frequency,
character, and severity of COPD exacerbations. Thorax 2002,
57(9):759–764.
41. Hartl D, Krauss-Etschmann S, Koller B, Hordijk PL, Kuijpers TW, Hoffmann F,
Hector A, Eber E, Marcos V, Bittmann I, Eickelberg O, Griese M, Roos D:
Infiltrated neutrophils acquire novel Chemokine receptor expression
and Chemokine responsiveness in chronic inflammatory lung diseases.
J Immunol 2008, 181(11):8053–8067.
42. Houssiau FA, Devogelaer JP, Van Damme J, Nagant de Deux-chaisnes C,
Van Snick J: Interleukin-6 in synovial fluid and serum of patients with
rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum
1988, 31(6):784–788.
43. Atreya R, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B,
Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehir HA, Autscbach F,
Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-
John S, Neurath MF: Blockade of interleukin-6 trans-signalling suppresses
Ravi et al. Respiratory Research 2014, 15:103 Page 10 of 10
http://respiratory-research.com/content/15/1/103T cell resistance against apoptosis in chronic intestinal inflammation:
evidence in Crohn’s disease and experimental colitis in vivo. Nat Med
2000, 6(5):583–588.
44. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS,
Dong C: STAT 3 regulates cytokine mediated generation of inflammatory
helper T cells. J Biol Chem 2007, 282(13):9358–9363.
doi:10.1186/s12931-014-0103-4
Cite this article as: Ravi et al.: Increased levels of soluble interleukin-6
receptor and CCL3 in COPD sputum. Respiratory Research 2014 15:103.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
